Pages that link to "Q34507966"
Jump to navigation
Jump to search
The following pages link to MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. (Q34507966):
Displayed 16 items.
- First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response (Q33777877) (← links)
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment (Q35787908) (← links)
- Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme (Q36525099) (← links)
- Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas (Q37409721) (← links)
- The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline (Q38623610) (← links)
- Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. (Q38623612) (← links)
- Curcumin Reactivates Silenced Tumor Suppressor Gene RARβ by Reducing DNA Methylation (Q38874057) (← links)
- Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase (Q39229754) (← links)
- Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss (Q42376082) (← links)
- IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas (Q48618352) (← links)
- MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors (Q48686096) (← links)
- Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide (Q48863873) (← links)
- MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis (Q48873373) (← links)
- CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. (Q50709265) (← links)
- Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. (Q55459936) (← links)
- TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. (Q55461118) (← links)